Putting the brakes on home genetic testing: Four questions with geneticist Scott Diehl

December 4, 2013 by Rob Forman

The Food and Drug Administration recently ordered an end to sales of the home genetic testing kit 23andMe. FDA medical experts said the kit's manufacturers had failed to prove their claim that the $99 test can help customers make informed decisions about their health, despite being asked for that proof for more than five years. 23andMe says that in 2013, more than 200,000 people have purchased its product.

According to the company's website, by analyzing DNA from a sample of a customer's saliva, "23andMe helps you know more about your health so you can take an active role in managing it." But the FDA says that customers may be risking their lives if they rely on test results to make important health-related decisions.

Scott Diehl is director of the Center for Pharmacogenomics and Complex Disease Research at the Rutgers School of Dental Medicine, and a longtime critic of tests such as 23andMe, which derives its name from the fact that human cells contain 23 pairs of chromosomes. Diehl says ordering the test off the market was the right decision.

What is wrong with letting consumers buy a product that tells them more about their DNA than they knew before?

The picture the test gives people is so incomplete as to make it useless. For years, 23AndMe has been telling unsophisticated consumers that their risk of highly complex disorders such as diabetes, rheumatoid arthritis, Celiac disease, heart disease, stroke and schizophrenia is higher or lower based on just one or two inherited genetic variations. Most geneticists are convinced that risk of these diseases is determined by thousands of variants. Relying on these home testing kits is like predicting whether your car will break down during a long journey after you've only checked whether a couple of lug nuts on one of the wheels are sufficiently tight.

But even if the information is limited, is there any harm in it?

These incomplete tests for complex diseases may mislead people into thinking their risk is higher or lower than it really is, and they might fail to take important steps such as weight loss, improvements in diet or increased exercise because of a false report of low risk for a condition such as diabetes or .

What about tests for certain life-threatening illnesses?

Tests that predict a person's risk for deadly conditions like breast cancer or serious side effects of medications really have no place in the direct-to-consumer market. These tests require guidance and interpretation by doctors and trained genetic counselors because decisions can have major health consequences as well as psychological effects on the patient and family members. Few people without medical training have sufficient knowledge to understand what such tests really mean. The tests' limitations could scare some people unnecessarily while lulling others into a false complacency so that they fail to follow up with their doctors and get the far more rigorous and comprehensive testing that can be performed by a medical genetics laboratory.

Could further advances in testing technology, knowledge of genetics or added safeguards make home genetic testing acceptable to you in the future?

Although the cost of DNA assays has been coming down very rapidly, the challenge of interpreting the deluge of data has gotten far greater. Testing for diseases that have serious needs to be very carefully controlled. Today there are dozens of companies aggressively marketing tests for health conditions for which there is little or no clinical validation. It is in the public interest for the FDA to provide oversight of this growing industry so that consumers aren't paying for worthless information and so the have well-documented clinical validity just as the FDA requires for drugs and medical devices.

Explore further: US tells 23andMe to halt sales of genetic test

Related Stories

US tells 23andMe to halt sales of genetic test

November 25, 2013
The U.S. Food and Drug Administration is ordering genetic test maker 23andMe to halt sales of its personalized DNA test kits, saying the company has failed to show that the technology is backed by science.

It is game over for 23andMe, and rightly so

November 27, 2013
The market for personal genome services is facing a reality check. While the most prominent and innovative company 23andMe has flourished so far, in the past few years many of its competitors have gone out of business. Now, ...

23andMe faces class action lawsuit in California

December 3, 2013
Genetic testing company 23andMe is facing a class action lawsuit alleging that the Silicon Valley startup misled customers about its test kit.

Study finds that Americans want doctors' guidance on genetic test results

November 7, 2013
In an era of commercialized medicine, direct-to-consumer (DTC) genetic testing has been on a steady rise. Consumers can purchase a DNA sample kit, also known as a "spit kit," mail it to a testing company, and wait for an ...

Direct-to-consumer genetic testing kits vary in predictions of disease risk

July 17, 2013
(Medical Xpress)—An in-depth analysis and comparison study conducted by investigators at Emory's Rollins School of Public Health demonstrated variations in predicted disease risks by companies that offer direct-to-consumer ...

Comparing family history and genetic tests for predicting complex disease risk

October 15, 2012
In a new theoretical study, 23andMe, the personal genetics company, developed a mathematical model which shows that family history and genetic tests offer different strengths. The study results suggest that both family history ...

Recommended for you

A rogue gene is causing seizures in babies—here's how scientists wants to stop it

July 26, 2017
Two rare diseases caused by a malfunctioning gene that triggers seizures or involuntary movements in children as early as a few days old have left scientists searching for answers and better treatment options.

Scientists provide insight into genetic basis of neuropsychiatric disorders

July 21, 2017
A study by scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) is providing insight into the genetic basis of neuropsychiatric disorders. In this research, the first mouse model of a mutation ...

Scientists identify new way cells turn off genes

July 19, 2017
Cells have more than one trick up their sleeve for controlling certain genes that regulate fetal growth and development.

South Asian genomes could be boon for disease research, scientists say

July 18, 2017
The Indian subcontinent's massive population is nearing 1.5 billion according to recent accounts. But that population is far from monolithic; it's made up of nearly 5,000 well-defined sub-groups, making the region one of ...

Mutant yeast reveals details of the aberrant genomic machinery of children's high-grade gliomas

July 18, 2017
St. Jude Children's Research Hospital biologists have used engineered yeast cells to discover how a mutation that is frequently found in pediatric brain tumor high-grade glioma triggers a cascade of genomic malfunctions.

Late-breaking mutations may play an important role in autism

July 17, 2017
A study of nearly 6,000 families, combining three genetic sequencing technologies, finds that mutations that occur after conception play an important role in autism. A team led by investigators at Boston Children's Hospital ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.